论文部分内容阅读
临床应用发现顺铂具有耳毒性,其机制尚不清楚。为了研究高剂量顺铂治疗引起耳中毒的风险,对54例接受高剂量顺铂(100～120mg/m~2)治疗的转移癌患者进行了听力学监测。结果表明,81％的患者在完成治疗后,听力图出现明显的气导听力阈值的变化,发生了不同程度的听功能损伤;13％的患者有明显的听觉障碍;25％的患者在每一疗程后,高频听力损伤25％;41％的患者在完成治疗后,语言频率(0.5～2kHz)有明显的损失。但存在个体差异,有的患者在一个疗程后即产生了严重的耳聋,有的患者在3个疗程后仍无听力影响。对治疗前存在的听力下降,有不明显增加听力损伤的风险。但随着年龄增大,可使听功能损伤的风险略增加。每次用药剂量比累积应用剂量与听力损
Cisplatin is clinically found to have ototoxicity and its mechanism is unclear. To study the risk of ototoxicity induced by high-dose cisplatin, 54 patients with metastatic carcinoma undergoing high-dose cisplatin (100-120 mg / m 2) were followed up for audiological monitoring. The results showed that 81% of patients completed the treatment, the audiogram showed significant changes in air-conduction hearing threshold, the occurrence of varying degrees of hearing loss; 13% of patients had significant hearing impairment; 25% of patients in each After treatment, high-frequency hearing loss 25%; 41% of patients completed the treatment, the language frequency (0.5 ~ 2kHz) significant loss. However, there are individual differences. Some patients have severe deafness after one course of treatment. Some patients still have no hearing loss after 3 courses of treatment. Hearing loss before treatment, there is no significant increase in the risk of hearing loss. However, with increasing age, the risk of hearing impairment can be slightly increased. Each dose than the cumulative application dose and hearing loss